Online inquiry

IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9273MR)

This product GTTS-WQ9273MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CEACAM5 gene. The antibody can be applied in Colorectal Cancer (CRC) Cancers (CRC) Cancers (CRC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001291484.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1048
UniProt ID P06731
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ9273MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2238MR IVTScrip™ mRNA-Anti-VWF, aVWF81(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA aVWF81
GTTS-WQ13321MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-06741086
GTTS-WQ10867MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ7947MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ7198MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ7965MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GX-17
GTTS-WQ13787MR IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-10933
GTTS-WQ15212MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA TACI-Fc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW